Skip to main content
SpringerLink
Log in

Hautveränderungen nach Blockade des Epidermal-growth-factor-Rezeptors

Cutaneous lesions due to inhibition of epidermal growth factor receptor

  • Schwerpunkt: Iatrogene Pathologie
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Maligne Tumoren werden zusehends mit Therapeutika behandelt, deren Wirkmechanismen auf molekularer Ebene ansetzen (so genannte Biologics). Dazu gehören Therapeutika zur Blockade des epidermalen Wachstumsfaktor-Rezeptors (EGFR). Das Profil der Nebenwirkungen beim Einsatz von EGFR-Inhibitoren wird wesentlich durch Hautveränderungen bestimmt. Führend sind akneiforme Hautreaktionen gefolgt von Xerose, Ekzemen sowie Haar- und Nagelveränderungen. Die Hautveränderungen sind individuell sehr unterschiedlich ausgeprägt, können weitgehend unauffällig sein, können aber auch eine Fortsetzung der Therapie verhindern. Bei der Anwendung von EGFR-Inhibitoren wurde eine Korrelation zwischen dem Schweregrad der Hautveränderungen und dem Wirkungsgrad des Therapeutikums beobachtet, was für eine individuelle Dosisanpassung potenzielle Bedeutung hat.

Abstract

Malignant tumors are increasingly being treated with therapeutic agents having molecular mechanisms of action (so-called biologics). These include therapeutic agents for the blockade of epidermal growth factor receptor (EGFR). The adverse drug reaction profile associated with EGFR inhibitors is dominated by cutaneous lesions. Most common are acneiform skin reactions followed by xerosis, eczema and changes to the hair and nails. The cutaneous changes vary greatly between individuals and may be relatively insignificant. However, they may also prevent continuation of therapy. During the use of EGFR inhibitors, a correlation was observed between the severity of cutaneous changes and the effectiveness of the therapeutic agent, a finding potentially useful for individual dose adjustment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Albanell J, Rojo, F, Averbuch S et al. (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer paptients. J Clin Oncol 20:110–124

    PubMed  Google Scholar 

  2. Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 [Suppl 4]:2–8

    PubMed  Google Scholar 

  3. Baselga J, Rischin D, Ranson M et al. (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292–4302

    PubMed  Google Scholar 

  4. Bork K (Hrsg) (1999) Arzneimittelnebenwirkungen an der Haut. Schattauer, Stuttgart NewYork

  5. Branzan AL, Landthaler M, Szeimies RM (2005) Hautveränderungen unter Chemotherapie. Hautarzt 56:591–603

    PubMed  Google Scholar 

  6. Busam KJ, Capodieci P, Motzer R et al. (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169–1176

    PubMed  Google Scholar 

  7. Chua DT, Nicholls JM, Sham JS et al. (2004) Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59:11–20

    Article  Google Scholar 

  8. Ciardiello F, Tortora G (2002) Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs 11:755–768

    PubMed  Google Scholar 

  9. Clark MA, Fisher C, Judson I, Thomas M (2005) Soft-tissue sarcomas in adults. N Eng J Med 353:701–711

    Article  Google Scholar 

  10. Cunninham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med 351:337–345

    Article  Google Scholar 

  11. Fan Z, Masui H, Altas I et al. (1993) Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53:4322–4328

    PubMed  Google Scholar 

  12. Jacot W, Bessis D, Jorda E et al. (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151:238–241

    PubMed  Google Scholar 

  13. Herbst RS, LoRusso PM, Purdom M et al. (2003) Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 4:366–369

    PubMed  Google Scholar 

  14. Hidalgo M, Siu LL, Nemunaitis J et al. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267–3277

    PubMed  Google Scholar 

  15. Kimyai-Asadi A, Jih MH (2002) Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 138:129–131

    PubMed  Google Scholar 

  16. Lee MW, Seo CW, Kim SW et al. (2004) Cutaneous side effects in non-small cell lung cancer (patients treated with Iressa ZD1839), an inhibitor of epidermal growth factor receptor. Acta Derm Venerol 84:23–26

    PubMed  Google Scholar 

  17. Milas L, Fan Z, Andratschke NH et al. (2004) Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58:966–971

    PubMed  Google Scholar 

  18. Nanney L, Magid M, Stoscheck C et al. (1984) Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 83:385–393

    PubMed  Google Scholar 

  19. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4:9-15

    Article  Google Scholar 

  20. Perez-Soler R (2003) Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 17:23–28

    Google Scholar 

  21. Perez-Soler R, Chachoua A, Hammond LA et al. (2004) Determinants of tumour response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238–3247

    PubMed  Google Scholar 

  22. Purdom M (2004) Management of acneiform rashes related to gefitinib therapy. Clin J Oncol Nurs 8:316–317

    PubMed  Google Scholar 

  23. Rowinsky EK, Schwartz GH, Gollob JA et al. (2004) Safety, pharmacokinetics and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cancer. J Clin Oncol 22:3003–3015

    PubMed  Google Scholar 

  24. Saltz L, Kies M, Abbruzzese JL et al. (2003) The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22: Abstract 817

    Google Scholar 

  25. Saltz L, Meropol NJ, Loehrer PJ et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208

    Article  PubMed  Google Scholar 

  26. Segaert S, Tabernero J, Chosidow O et al. (2005) The management of skin reactions in cancer patients receiving epidermal growth factor targeted therapies. J Dtsch Dermatol Ges 3:599–606

    PubMed  Google Scholar 

  27. Seymour LK ( 2001) Epidermal growth factor receptor as a target: recent developments in the search for effective new anti-cancer agents. Curr Drug Targets 2:117–133

    PubMed  Google Scholar 

  28. Shah NT, Kris MG, Pao W et al. (2005) Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23:165–174

    Article  PubMed  Google Scholar 

  29. Van Doorn RK, Scheffer E, Stoof TJ, Giaccone G (2002) Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147:598–601

    Article  PubMed  Google Scholar 

  30. Yarden Y (2001) The EGFR family and its ligands in human cancer, signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 [Suppl 4]:3–8

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Institut für Dermatopathologie, Bonn

    E. Bierhoff & H. W. Seifert

  2. Praxis für Dermatologie, Wuppertal

    T. Dirschka

  3. Institut für Dermatopathologie, Trierer Straße 70–72, 53115, Bonn

    E. Bierhoff

Authors
  1. E. Bierhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. W. Seifert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Dirschka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Bierhoff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bierhoff, E., Seifert, H.W. & Dirschka, T. Hautveränderungen nach Blockade des Epidermal-growth-factor-Rezeptors. Pathologe 27, 53–56 (2006). https://doi.org/10.1007/s00292-005-0803-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-005-0803-0

Schlüsselwörter

Keywords

Search

Navigation